AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Method to transduce leukemia B cells developed.
2002 NOV 27 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A research team from Ludwig-Maximilians-University in Munich have developed a method to transduce B cells of chronic lymphocytic leukemia using adeno-associated virus vectors, opening the door to creating vaccines against CLL.
The B cells of chronic lymphocytic leukemia (B-CLL) have proven resistant to transduction using established vectors. However, Clemens-Martin Wendtner and his colleagues developed an adenovirus-free system through which they were able to transfect B-CLL with recombinant adeno-associated virus (rAAV) vectors coding for the enhanced green fluorescent protein (AAV/EGFP) or the CD40 ligand (AAV/CD40L).
The investigators transfected B-CLL from 24 patients with AAV/EGFP or AAV/CD40L. Flow cytometry indicated transgene expression in up to 97% of the cells within 48 hours following infection. Heparin was able to block the viral transduction.
The cells transduced with AAV/CD40L were able to up-regulate CD80 on infected leukemia cells as well as on uninfected "bystander" leukemia B cells, stimulating proliferation of allogeneic T cells with matching human leukocyte antigens (HLA).
"Vaccination strategies for patients with B-CLL using leukemia cells ...
- Targeted Genetics expands AAV patent portfolio, has exclusive rights to newly...
- Newspaper article from: BIOTECH Patent News July 1, 2004 700+ words
...the issuance of an additional patent broadening its AAV (adeno-associated viral) vector technology...Vectors and Host Cells Containing Same" covers AAV vectors with sequences from AAV serotype 1. The patent was issued to University...
- Targeted Genetics Expands AAV Patent Portfolio.
- Press release article from: PR Newswire July 7, 2004 700+ words
...the issuance of an additional patent broadening its AAV (adeno-associated viral) vector technology...Vectors and Host Cells Containing Same" covers AAV vectors with sequences from AAV serotype 1. The patent was issued to University...
- Avigen Licenses AAV Vector Technology to Stratagene.
- Press release article from: PR Newswire July 11, 2000 700+ words
...proprietary recombinant adeno-associated virus (AAV) vectors for research purposes. Stratagene...upfront payment and royalties on sales of the AAV kits and other products developed by Stratagene...based research tools, using Avigen's AAV technology. In addition, Avigen will receive...
- Targeted Genetics Receives AAV Manufacturing Patent Supporting AIDS Vaccine,...
- Press release article from: PR Newswire May 20, 2003 700+ words
...patent related to its adeno-associated virus (AAV) vector manufacturing process. U.S. patent...helper-free preparation of released recombinant AAV vectors." The patent describes an AAV manufacturing process in which the growth conditions...
- Targeted Genetics Expands AAV Manufacturing Patent Portfolio.
- Press release article from: PR Newswire November 5, 2003 700+ words
...related to its adeno-associated virus (AAV) vector production technology. U.S. patent...titled "Amplifiable Adeno-Associated Virus (AAV) Packaging Cassettes for the Production of Recombinant AAV Vectors," expands Targeted Genetics' production...
- Chronic Lymphocytic Leukemia (CLL) Patients Reach Five-Year Survival Milestone...
- Press release article from: PR Newswire May 3, 2005 700+ words
...traces of chronic lymphocytic leukemia (CLL) after receiving alemtuzumab had survived...detectable diseased cells in patients with CLL is associated with a prolonged overall and...monoclonal antibody approved for the treatment of CLL. "This study shows that it is possible...
- Avigen Issued patent for advanced AAV vector.(adeno-associated virus)(Brief...
- Newspaper article from: BIOTECH Patent News May 1, 2002 700+ words
...to its growing adeno-associated virus (AAV) vector patent portfolio with the issuance...titled "High-Efficiency Wild-Type-Free AAV Helper Functions." This composition of matter patent covers AAV vector free of wild-type AAV as determined...
- Avigen issued three patents expanding AAV portfolio.(adeno-associated virus...
- Newspaper article from: BIOTECH Patent News April 1, 2002 700+ words
...intellectual property portfolio in adeno-associated virus (AAV) vector technology. Two of the patents cover advances in the delivery of AAV. The third covers the cells used in Avigen's AAV manufacturing process, which result in significantly enhanced...
Source: HighBeam Research, Method to transduce leukemia B cells developed.